Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,803 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07102797Recruiting
ActiveGirls: Activity, hormones, and diabetes risk in young girls
This study looks at how physical activity and hormone health affect diabetes risk in young girls. It is for girls ages 8 to 12 who are at risk for PCOS (a hormone condition) and insulin resistance, and who have not yet started their period.
Somerville, MassachusettsAges 8 years+ - NCT07103148RecruitingPhase 3
Study of a Yellow Fever Vaccine in Young Children
This trial tests a new yellow fever vaccine in young children. It will see if the vaccine is safe and produces a good immune response, including when given with the MMR vaccine.
San Pedro SulaAges 9 months–5 years - NCT07103356Recruiting
Water pitcher filter to reduce arsenic in well water
This study gives eligible New Hampshire residents a special water pitcher filter that helps remove arsenic from well water. The study team will check if the filter works well over time and if people can use it easily at home.
Lebanon, New HampshireAges 18 years+ - NCT07104019Recruiting
Biofiller for Thinning Gums: A Gum-Thickening Study
This study tests a biofiller to make thin gums thicker in the lower front teeth area. It may help people with thin gums who want to improve their gum health and appearance.
MalatyaAges 18–65 - NCT07104058Recruiting
FAPI PET scan to predict relapse in IgG4-RD
This study tests whether a special PET scan (FAPI PET/CT) can detect tiny signs of disease activity (MRD) in people with stable IgG4-RD, and whether it helps predict who might relapse.
Beijing, Beijing MunicipalityAges 18–75 - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07104799RecruitingPhase 1
Momelotinib before and after stem cell transplant for myelofibrosis
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Boston, MassachusettsAges 18 years+ - NCT07106671RecruitingPhase 2
Siltuximab for side effects after CAR-T in multiple myeloma
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
TianjinAges 18 years+ - NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07110636Recruiting
Blood test for infection in immunocompromised adults
This trial tests a blood test that looks for infection by analyzing tiny bits of DNA from microbes. It may help find infections faster in people with weakened immune systems, such as transplant recipients or those with blood cancers.
San Francisco, CaliforniaAges 18 years+ - NCT07110922Recruiting
Pacing the heart's natural electrical highway: Bachmann bundle pacing study
This trial tests a special way to place a pacemaker lead that may improve heart function by pacing the Bachmann bundle, a key electrical pathway between the upper heart chambers. It is designed for people who already need a pacemaker or an ICD with an atrial lead.
Wilkes-Barre, PennsylvaniaAges 18 years+ - NCT07111208Recruiting
Air, noise, and lifestyle effects on heart health
This study tests if wearing a wristband that tracks air and noise can help reduce heart risks in people with early signs of metabolic syndrome. You will also get lifestyle tips to help protect your heart.
Kaunas, Kaunas CountyAges 45–64 - NCT07111598Recruiting
Iron supplements and the immune system in HHT
This study looks at how iron supplements affect the immune system in people with HHT (a genetic condition that causes bleeding from abnormal blood vessels). You may be placed in one of three groups depending on your iron and ferritin levels.
Bron, RhoneAges 18–99 - NCT07112066Recruiting
Heart imaging study for ATTR amyloidosis patients
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
Zurich, Canton of ZurichAges Any age - NCT07112170Recruiting
Radiation to slow melanoma growth after initial treatment
This study tests whether giving precise radiation to a limited number of growing spots can help control melanoma that has spread but is otherwise stable on immunotherapy or targeted therapy. You may join if you have up to 10 growing spots outside the brain that can be safely treated with focused radiation.
Toronto, OntarioAges 18 years+ - NCT07112183RecruitingPhase 4
Treprostinil study for Raynaud's attacks
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
Boston, MassachusettsAges 18 years+ - NCT07112287Recruiting
Germline testing for myeloid cancer risk
This trial studies whether certain inherited genes increase the risk of myeloid cancers or bone marrow failure. You will provide a DNA sample via a skin biopsy to look for these genetic changes.
Boston, MassachusettsAges 18 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,803 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.